MedTrace Logo

Pharmacogenomics of Interferon and Ribavirin Treatment in Patients With Chronic Hepatitis C Virus Infection

NCT00164073 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2007-08-01

No results posted yet for this study

Summary

The purpose of this study is to examine gene expression profiles by DNA microarray in patients who are responders and non-responders to interferon and ribavirin treatment for hepatitis C virus (HCV). Genes involved in inflammation and fibrosis and mediators of the Th-1 lymphocyte response will be looked for. It is hoped that genetic targets for future more effective and less toxic treatments will be identified.

Conditions

  • Hepatitis C

Interventions

PROCEDURE

Liver biopsy

Sponsors & Collaborators

  • University of Adelaide

    collaborator OTHER

  • Bayside Health

    lead OTHER_GOV

Principal Investigators

  • Mark D Berzsenyi, MBBS · The Alfred

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-02-29
Completion
2007-02-28

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00164073 on ClinicalTrials.gov